{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216710","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2026-05-11T20:02:33+00:00","discovered_at":"2026-05-11T20:04:03.457037+00:00","generated_at":"2026-05-11T22:57:36.763038+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Galera shareholders approve reverse split (1:75 to 1:200) and share increase to 400M","bullets":["Elected J. Mel Sorensen (Class III), Nancy Chang and Michael Friedman (Class I) as directors.","Ratified KPMG as auditor for FY 2026.","Approved say-on-pay and annual frequency for future say-on-pay votes.","Authorized amendment raising common shares from 200M to 400M.","Authorized reverse stock split at Board-discretion ratio between 1:75 and 1:200."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216710","json":"https://secwatch.observer/filing/0001193125-26-216710.json","markdown":"https://secwatch.observer/filing/0001193125-26-216710.md","text":"https://secwatch.observer/filing/0001193125-26-216710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/d137690d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:57:36.763038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b6781b0c56f4d8aff8af6ca860ef0d9e2153dc7","claim":"Galera Therapeutics, Inc. shareholders approved Advisory Vote on Frequency of Future Say-On-Pay Votes (every one year) at the 2026-05-08 meeting.","evidence_excerpt":"Proposal 4—Advisory Vote on Frequency of Future Say-On-Pay Votes: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 108,127,837 64,666 3,611,866 1,076,074 10,877,949","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"17ec96d4498d4e818783d0f828e8f32762b08845","claim":"Galera Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-08 meeting.","evidence_excerpt":"At the combined 2025 and 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) of Galera Therapeutics, Inc. (the “ Company ”) held on May 8, 2026, the Company’s stockholders (i) elected (A) one Class III director to the board of directors of the Company (the “ Board ”), to serve until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified, and (B) two Class I directors to the Board, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"38e885d358d84ab33805e01aae7a5fe011845eaf","claim":"Galera Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-08 meeting.","evidence_excerpt":"Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm: Votes For Votes Against Abstentions 121,742,195 1,961,191 55,006","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"3c65d04f9fce647de6d261846d7f6b539e5ce781","claim":"Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Increase Authorized Capital Stock from 200 million shares to 400 million shares at the 2026-05-08 meeting.","evidence_excerpt":"Proposal 5—Approval of Charter Amendment to Increase Authorized Capital Stock: Votes For Votes Against Abstentions 120,916,020 2,745,505 96,867","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"516881163d2b55307d673f97ac37b8da6f41b26b","claim":"Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Provide Written Consent Right at the 2026-05-08 meeting.","evidence_excerpt":"Proposal 6—Approval of Charter Amendment to Provide Written Consent Right: Votes For Votes Against Abstentions Broker Non-Votes 112,456,777 417,500 6,166 10,877,949","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"5aa90b3ff67204fc12de1ed33ce597ba3fb76d6f","claim":"Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Effect a Reverse Stock Split at a ratio between 1:75 and 1:200, if and when determined by the Board at the 2026-05-08 meeting.","evidence_excerpt":"Proposal 7—Approval of Charter Amendment to Effect a Reverse Stock Split: Votes For Votes Against Abstentions 121,087,262 2,639,613 31,517","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"d64705c84a8db0e8e2452cd7d3b2f50a7ebb3313","claim":"Galera Therapeutics, Inc. shareholders approved Approval of compensation paid to the Company’s named executive officers (Say-on-Pay) at the 2026-05-08 meeting.","evidence_excerpt":"Proposal 3—Say-on-Pay Vote: Votes For Votes Against Abstentions Broker Non-Votes 108,167,385 3,690,210 1,022,848 10,877,949","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526216710/0001193125-26-216710-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}